Frequent distribution of ultrarapid metabolizers of debrisoquine in an ethiopian population carrying duplicated and multiduplicated functional CYP2D6 alleles

Journal of Pharmacology and Experimental Therapeutics

Volumn 278, Issue 1, 1996, Pages 441-446

  Aklillu, Eleni ^a   Persson, Irene ^b   Bertilsson, Leif ^c   Johansson, Inger ^b   Rodrigues, Fredrick ^a   Ingelman Sundberg, Magnus ^b  

^a ADDIS ABABA UNIVERSITY   (Ethiopia)

^b KAROLINSKA INSTITUTE   (Sweden)

^c KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

DEBRISOQUINE; OXYGENASE;

ALLELE; ARTICLE; CLINICAL TRIAL; DRUG HYDROXYLATION; DRUG METABOLISM; ETHIOPIA; GENE DUPLICATION; GENE MUTATION; GENOTYPE; HUMAN; HUMAN EXPERIMENT; NORMAL HUMAN; PHENOTYPE; PRIORITY JOURNAL;

EID: 0030432585     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (29)

1. AGÚNDEZ, J. A. G., LEDESMA, M. C., LADERO, J. M. AND BENITEZ, J.: Prevalence of CYP2D6 gene duplication and its repercussion on the oxidative phenotype in a white population. Clin. Pharmacol. Ther. 57: 265-269, 1995.
2. BERTILSSON, L., ÅBERG-WISTEDT, A., GUSTAFSSON, L. L. AND NORDIN, C.: Extremely rapid hydroxylation of debrisoquine: A case report with implications for treatment with nortriptyline and other tricyclic antidepressants. Ther. Drug. Monit. 7: 478-480, 1985.
3. BERTILSSON, L., DAHL, M.-L., INGELMAN-SUNDBERG, M., JOHANSSON, I. AND SJÖQVIST, F.: Interindividual and interethnic differences in polymorphic drug oxidation - Implications for drug theraphy with focus on psychoactive drugs. In Advances in Drug metabolism in Man, ed. by G. Pacifici and G. N. Fracchia, pp. 85-136, EUR 15439 EN, EC, Luxembourg: Office for Official Publications of the European Communities, DGXII-E-4, 1995.
4. BERTILSSON, L., DAHL, M.-L., SJÖQVIST, F., ÅBERG-WISTEDT, A., HUMBLE, M., JOHANSSON I., LUNDQVIST, E. AND INGELMAN-SUNDBERG, M.: Molecular basis for rational mega-prescribing in ultrarapid hydroxylators of debrisoquine. Lancet 341: 63, 1993.
5. BR[SWS]SEN, K.: Isozyme specific drug oxidation: Genetic polymorphism and drug-drug interactions. Nord. J. Psychiatry 47: 21-26, 1993.
6. DAHL, M. L., JOHANSSON, I., BERTILSSON, L., INGELMAN-SUNDBERG, M. AND SJÖQVIST, F.: Ultrarapid hydroxylation of debrisoquine in a Swedish population. Analysis of the molecular genetic basis. J. Pharmacol. Exp. Ther. 274: 516-520, 1995.
7. EICHELBAUM, M. AND GROSS, A. S.: The genetic polymorphism of debrisoquine/ sparteine metabolism - Clinical aspects. Pharmacol. Ther. 46: 377-394, 1990.
8. EVANS, W. E., RELLING, M. V., RAHMAN, A., MCLEOD, H. L., SCOTT, E. P. AND LIN, J. S.: Genetic basis for low prevalence of deficient CYP2D6 oxidative drug metabolism in black Americans. J. Clin. Invest. 91: 2150-2154, 1993.
9. DE SOMMERS, K., MONCRIEFF, J. AND AVENANT, J.: Non-correlations between debrisoquine and metoprolol polymorphism in the Venda. Human Toxicol. 8: 365-368, 1989.
10. GAEDIGK, A., BLUM, M., GAEDIGK, R., EICHELBAUM, M. AND MEYER, U. A.: Deletion of the entire cytochrome P450 CYP2D6 gene as a cause of impaired drug metabolism in poor metabolizers of the debrisoquine/sparteine polymorphism. Am. J. Humum Genet. 48: 943-950, 1991.
11. HEIM, M. H. AND MEYER, U. A.: Genotyping of poor metabolisers of debrisoquine by allele-specific PCR amplification. Lancet ii: 529-532, 1990.
12. HEIM, M. H. AND MEYER, U. A.: Evolution of a highly polymorphic human cytochrome P450 gene cluster: CYP2D6. Genomics 14: 49-58, 1992.
13. INGELMAN-SUNDBERG, M. AND JOHANSSON, I.: The molecular genetics of the human drug metabolizing cytochrome P450S. In Advances in Drug metabolism in Man, ed. by G. Pacifici and G. N. Fracchia, pp. 543-586, EUR 15439 EN, EC, DGXII-E-4, Luxembourg: Office for Official Publications of the European Communities, 1995.
14. JOHANSSON, I., LUNDQVIST, E., BERTILSSON, L., DAHL, M.-L., SJÖQVIST, F. AND INGELMAN-SUNDBERG M.: Inherited amplification of an active gene in the cytochrome P4502D locus as a cause of ultrarapid metabolism of debrisoquine. Proc. Natl. Acad. Sci. U.S.A. 90: 11825-11829, 1993.
15. JOHANSSON, I. OSCARSON, M., YUE, Q.-Y., BERTILSSON, L., SJÖQVIST, F. AND INGELMAN-SUNDBERG, M.: Genetic analysis of the Chinese CYP2D locus. Characterization of variant CYP2D6 genes present in subjects with diminished capability for debrisoquine hydroxylation. Mol. Pharmacol. 46: 452-459, 1994.
16. JOHANSSON, I., YUE, Q.-Y., DAHL, M.-L., HEIM, M., SÄWE, J., BERTILSSON, L., MEYER, U. A., SJÖQVIST, F. AND INGELMAN-SUNDBERG, M.: Genetic analysis of the interethnic difference between Chinese and Caucasians in the polymorphiic metabolism of debrisoquine and codeine. Eur. J. Clin. Pharmacol. 40: 553-556, 1991.
17. KALOW, W. AND BERTILSSON, L.: Interethnic factors affecting drug response. Adv. Drug. Res. 25: 1-53, 1994.
18. KIMURA, S., UMENO, M., SKODA, R. C., MEYER, U. A. AND GONZALEZ, F. J.: The human debrisoquine 4-hydroxylase (CYP2D) locus. Sequence and identification of the polymorphic CYP2D6 gene, a related gene and a pseudogene. Am. J. Humun Genet. 45: 889-904, 1989.
19. LENNARD, M. S., IYUN, A. O., JACKSON, P. R., TUCKER, G. T. AND WOODS, H. F.: Evidence for a dissociation in the control of sparteine, debrisoquine and metoprolol metabolism in Nigerians. Pharmacogenetics 2: 89-92, 1992.
20. LENNARD, M. S., SILAS, J. H., SMITH, A. J. AND TUCKER, G. T.: Determination of debrisoquine and its 4-hydroxymetabolite in biological fluids by gas chromatography with flame ionization and nitrogen detection. J. Chromatogr. 133: 161-166, 1977.
21. MAHGOUB, A., IDLE, J. R. AND SMITH, R. L.: A population and familial study of defective alicyclic hydroxylation of debrisoquine among Egyptians. Xenobiotica 9: 51-56, 1979.
22. MASIMIREMBWA, C. M.: Pharmacogenetics of drug metabolizing enzymes in a black African population. Thesis, Karolinska institutet, 1995.
23. MASIMIREMBWA, C. M., JOHANSSON, I., HASLER, J. A. AND INGELMAN-SUNDBERG, M.: Genetic polymorphism of cytochrome P450 2D6 in a Zimbabwean population. Pharmacogenetics 3: 275-280, 1993.
24. MBAFENO, C., BABABUNMI, D., MAHGOUB, A., SLOAN, T. P., IDLE, J. R. AND SMITH, R. L.: A study of debrisoquine hydroxylation polymorphism in a Nigerian population. Xenobiotica 10: 811-818, 1980.
25. SANZ, E. J., VILLEN, T., ALM, C. AND BERTILSSON, L.: S-Mephenytoin hydroxylation phenotypes in a Swedish population determined after coadministration with debrisoquine. Clin. Pharm. Ther. 45: 495-499, 1989.
26. SIMOOYA, O. O., NJUNJU, E., HODJEGAN, A. R., LENNARD, M. S. AND TUCKER, G. T.: Debrisoquine and metoprolol oxidation in Zambians: A population study. Pharmacogenetics 3: 205-208, 1993.
27. TYNDALE, R., AOYAMA, T., BROLY, F., MATSUNAGA, T., INABA, T., KALOW, W., GELBOIN, H. V., MEYER, U. A. AND GONZALEZ, F. J.: Identification of a new variant CYP2D6 allele lacking the codon encoding Lys-281: Possible association with the poor metabolizer phenotype. Pharmacogenetics 1: 26-32, 1991.
28. WOOLHOUSE, N. M., ANDOH, B., MAHGOUB, A., SLOAN, T. P., IDLE, J. R. AND SMITH, R. L.: Debrisoquine hydroxylation polymorphism among Ghanaians and Caucasians. Clin. Pharmacol. Ther. 26: 584-591, 1979.
29. WOOLHOUSE, N. M., EICHELBAUM, M., OATES, N. S., IDLE, J. R. AND SMITH, R. L.: Dissociation of coregulatory control of debrisoquine/phenformin and spareine oxidation in Ghanaians. Clin. Pharmacol. Ther. 37: 512-521, 1985.